UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 血管新生阻害剤の概要 overview of angiogenesis inhibitors
2. 難治性狭心症マネージメントのための血管新生療法 therapeutic angiogenesis for management of refractory angina
3. 上皮性卵巣癌、卵管癌、または腹膜癌における血管新生阻害剤の作用 the role of angiogenesis inhibitors in epithelial carcinoma of the ovary fallopian tube or peritoneum
4. 下肢末梢動脈疾患の症状を治療するための試験的治療 investigational therapies for treating symptoms of lower extremity peripheral artery disease
5. 糖尿病性網膜症：分類および臨床的特徴 diabetic retinopathy classification and clinical features

English Journal

The efficacy and safety of a novel posterior scleral reinforcement device in rabbits.

Yuan Y1, Zong Y1, Zheng Q1, Qian G2, Qian X1, Li Y1, Shao W1, Gao Q3.
Materials science & engineering. C, Materials for biological applications.Mater Sci Eng C Mater Biol Appl.2016 May 1;62:233-41. doi: 10.1016/j.msec.2015.12.046. Epub 2016 Jan 14.
PURPOSE: To evaluate the efficacy and safety of posterior scleral reinforcement (PSR) device for myopia suppression in rabbits' eyes.METHODS: PSR surgery was performed on the normal 12 8-week-old New Zealand white rabbits' right eyes. To determine efficacy of the device, ophthalmic examination would
PMID 26952419

The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook.

Munk MR1,2, Rückert R3, Zinkernagel M1, Ebneter A1, Wolf S1.
Expert opinion on biological therapy.Expert Opin Biol Ther.2016 Apr;16(4):477-87. doi: 10.1517/14712598.2016.1132696. Epub 2016 Feb 12.
INTRODUCTION: The global prevalence of pathologic myopia is 0.9-3.1%, and visual impairment is found in 0.1-0.5% of European and 0.2-1.4% of Asian studies. Myopic choroidal neovascularization (mCNV) affects 5.2-11.3% of pathologic myopia patients and is a leading cause of vision impairment in the wo
PMID 26666589

Synthesis of a bi-functional dendrimer-based nanovehicle co-modified with RGDyC and TAT peptides for neovascular targeting and penetration.

Li J1, Zhang X2, Wang M1, Li X1, Mu H1, Wang A1, Liu W3, Li Y3, Wu Z4, Sun K5.
International journal of pharmaceutics.Int J Pharm.2016 Mar 30;501(1-2):112-23. doi: 10.1016/j.ijpharm.2016.01.068. Epub 2016 Jan 29.
The dual-ligand dendritic polyamidoamine-(polyethylene glycol)n-cyclic RGDyC peptide-(TAT peptide) (PPnR(T)) with various supplied molar ratios of polyethylene glycol (PEG) to polyamidoamine (PAMAM) (n=5, 15, 30) were designed as drug-carriers for the treatment of neovascular diseases; their targeti
PMID 26828670